Table 2.
Cross-species intersection of plasma protein signatures of MEN1-related dpNET progression
| MEN1-PanNET micea | |||||
|---|---|---|---|---|---|
| 8 month | 12 month | Human MEN1 cohort | |||
| Protein | Description | Fold-changea | Fold-changea | AUCb | 95% CI |
| NDC80 | Kinetochore protein NDC80 | 3.58 | 4.30 | 0.84 | 0.64-1.00 |
| DEF8 | Differentially expressed in FDCP 8 homolog | 3.58 | 3.32 | 0.77 | 0.60-0.93 |
| SPAG17 | Sperm associated antigen 17 | 1.93 | 1.32 | 0.82 | 0.59-1.00 |
| ATM | ATM serine/threonine kinase | 1.54 | 1.99 | 0.66 | 0.50-0.82 |
| IMMT | Inner membrane mitochondrial protein | 1.36 | 2.95 | 0.77 | 0.57-0.96 |
| DNAH6 | Dynein axonemal heavy chain 6 | 1.32 | 1.55 | 0.69 | 0.50-0.88 |
| DSP | Desmoplakin | 1.31 | 1.57 | 0.77 | 0.49-1.00 |
| CIT | Citron Rho-interacting serine/threonine kinase | 1.22 | 6.16 | 0.75 | 0.56-0.94 |
| C3 | Complement C3 | 1.16 | 1.43 | 0.67 | 0.53-0.82 |
| HRG | Histidine rich glycoprotein | 1.15 | 1.24 | 0.66 | 0.49-0.82 |
| F5 | Coagulation factor V | 1.14 | 1.26 | 0.75 | 0.60-0.89 |
| CD79A | Cluster of differentiation CD79A | 1.08 | 3.22 | 0.69 | 0.44-0.95 |
| BDP1 | B double prime 1 | 1.07 | 2.86 | 0.68 | 0.53-0.84 |
| SERPINA11 | Serpin family A member 11 | 1.06 | 1.44 | 0.75 | 0.60-0.90 |
| PROS1 | Coagulation regulator protein S | 1.06 | 1.43 | 0.69 | 0.53-0.84 |
| TARBP1 | TAR (HIV-1) RNA binding protein 1 | 1.05 | 1.31 | 0.84 | 0.65-1.00 |
| B2M | B2 microglobulin | 1.02 | 1.25 | 0.68 | 0.52-0.84 |
| SERPIND1 | Serpin family D member 1 | 1.02 | 1.21 | 0.70 | 0.54-0.85 |
| PROC | Protein C | 1.00 | 1.23 | 0.68 | 0.53-0.84 |
Abbreviations: AUC, area under the receiver operating characteristics curve; CI, confidence interval; dpNET, duodenopancreatic neuroendocrine tumor.
a Fold change comparing plasma protein levels between cases (Men1fl/flPdx1-CreTg) and control (Men1fl/fl) mice.
b Predictive performance (AUC) for distinguishing cases from respective controls. Cases are defined as patients with MEN1 and liver metastases from a duodenopancreatic neuroendocrine tumor (dpNET). Controls are patients with MEN1 and a nonmetastatic (distant or regional) indolent dpNET or patients with MEN1 without a dpNET or other neuroendocrine tumor.